Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$38.70 USD
-0.47 (-1.20%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $38.67 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Amphastar Pharmaceuticals (AMPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$61.33 | $71.00 | $50.00 | 56.57% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Amphastar Pharmaceuticals comes to $61.33. The forecasts range from a low of $50.00 to a high of $71.00. The average price target represents an increase of 56.57% from the last closing price of $39.17.
Analyst Price Targets (6 )
Broker Rating
Amphastar Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy, representing 71.43% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/26/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
5/2/2024 | Capital One Securities | Timothy Chiang | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Serge Belanger | Hold | Hold |
11/13/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/30/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 7 |
Average Target Price | $61.33 |
LT Growth Rate | 15.80% |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 171 of 252 |
Current Quarter EPS Est: | 0.78 |